Skip to main content
main-content

Rheumatology

Latest articles

21-09-2017 | Rheumatology | News

News in brief

Better PROs with baricitinib versus methotrexate

Baricitinib treatment is associated with greater improvements in patient-reported outcomes than methotrexate monotherapy, suggests an analysis of the RA-BEGIN trial.

19-09-2017 | Rheumatology | News | Article

Physical activity promotion needed after total knee or hip replacement

Changing sedentary behavior needs to be a focus for patients who undergo total knee or hip joint replacement, US researchers maintain.

Source:

Arthritis Care Res 2017: Advance online publication

18-09-2017 | Rheumatology | News | Article

RA disease activity and severity play ‘important role’ in reducing CVD risk

Targeting factors such as inflammation and disease activity in patients with rheumatoid arthritis could help reduce their risk for cardiovascular disease, study findings suggest.

Source:

Ann Rheum Dis 2017; Advance online publication

15-09-2017 | Rheumatology | News | Article

News in brief

Predictors of medication adherence in RA patients identified

A Canadian research team has pinpointed several sociodemographic, disease, and treatment parameters associated with adherence to medication in patients with rheumatoid arthritis.

13-09-2017 | Rheumatology | News

News in brief

Herpes zoster infection ‘one potential trigger’ for giant cell arteritis

Results of a US study suggest that herpes zoster infection is associated with an increased risk for giant cell arteritis, but antiviral treatment and vaccination are unlikely to reduce this risk.

11-09-2017 | Rheumatology | News | Article

Weight loss supported for obese patients with gout

Evidence from a systematic review suggests that weight loss is likely to be beneficial for overweight and obese patients with gout.

Source:

Ann Rheum Dis 2017; Advance online publication

08-09-2017 | Rheumatology | Highlight | Article

Editor's pick

International recommendations for the use of biosimilars issued

An international taskforce has developed consensus-based recommendations for the evaluation and use of biosimilars to treat rheumatic diseases.

Source:

Ann Rheum Dis 2017; Advance online publication

07-09-2017 | Rheumatology | News | Article

Vaccination, monotherapy could reduce herpes zoster risk in tofacitinib-treated RA patients

Two studies published in Arthritis & Rheumatology explore strategies for reducing herpes zoster risk among patients with rheumatoid arthritis treated with the Janus kinase inhibitor tofacitinib.

Source:

Arthritis Rheumatol 2017; Advance online publication

06-09-2017 | Rheumatology | News | Article

Neutrophil-to-lymphocyte ratio may aid infection diagnosis in SLE

The ratio of absolute neutrophil to lymphocyte count could be an effective additional biomarker for detecting infection in patients with systemic lupus erythematosus, research suggests.

Source:

Clin Rheumatol 2017; Advance online publication

04-09-2017 | Rheumatology | News | Article

Sirukumab shows promise for patients with RA refractory to DMARDs

The interleukin-6 inhibitor sirukumab could offer a therapeutic option for patients with active rheumatoid arthritis despite treatment with disease-modifying antirheumatic drugs, results of the phase III SIRROUND-D study suggest.

Source:

Ann Rheum Dis 2017; Advance online publication

01-09-2017 | Rheumatology | News | Article

Predictors of uveitis in children with JIA identified

A Nordic cohort study has identified factors associated with the development of uveitis among children with juvenile idiopathic arthritis.

Source:

Pediatr Rheumatol Online J 2017; 15: 66

01-09-2017 | Rheumatology | News | Article

News in brief

IL-6R inhibitors an option for immunotherapy-induced arthritis

Treatment with interleukin-6 receptor blockers could be an effective option for patients with cancer who develop severe arthritis in response to immune checkpoint inhibition therapy, say researchers who describe three such cases in the Annals of the Rheumatic Diseases.

31-08-2017 | Rheumatology | News | Article

Editor's pick

Lifestyle modification might improve ULT response in gout patients

Dyslipidemia, abdominal obesity, and alcohol consumption are associated with a poor response to urate-lowering therapy among patients with gout, researchers report.

Source:

Arthritis Care Res 2017; Advance online publication

30-08-2017 | Rheumatology | News | Article

Ibuprofen associated with elevated blood pressure in patients with arthritis

Patients with osteoarthritis or rheumatoid arthritis who take ibuprofen are more likely to experience an increase in systolic blood pressure than those taking celecoxib, results of the PRECISION-ABPM study suggest.

Source:

ESC 2017; Barcelona, Spain
Eur Heart J 2017; Advance online publication

29-08-2017 | Rheumatology | News | Article

Long-term results support baricitinib for the treatment of RA

Open-label extension results from a phase IIb trial suggest that baricitinib continues to be well tolerated and efficacious for up to 2.5 years among patients with rheumatoid arthritis.

Source:

J Rheumatol 2017; Advance online publication

25-08-2017 | Rheumatology | News | Article

Trial results support intravenous golimumab for PsA

Intravenous golimumab is a promising treatment option for patients with psoriatic arthritis, results of the placebo-controlled GO-VIBRANT trial suggest.

Source:

Arthritis Rheumatol 2017; Advance online publication

25-08-2017 | Rheumatology | News | Article

approvalsWatch

FDA backs combination treatment for gout

Click through to read more on this decision

24-08-2017 | Rheumatology | News | Article

Editor's pick

Scoring system could aid biologic treatment choice for RA patients

A score calculated from laboratory results could help to identify whether patients with rheumatoid arthritis are more likely to respond to treatment with a tumor necrosis factor inhibitor or to the interleukin-6 inhibitor tocilizumab, researchers report.

Source:

Arthritis Res Ther 2017; 19: 185

23-08-2017 | Rheumatology | News | Article

Further evidence for equivalence of SB4 and etanercept

Two follow-up analyses of a randomized trial suggest that the etanercept biosimilar SB4 and its reference product have similar long-term efficacy and safety profiles in patients with rheumatoid arthritis, and switching to the biosimilar is not associated with adverse events or loss of response.

Source:

Rheumatology 2017; Advance online publication
Ann Rheum Dis 2017; Advance online publication

22-08-2017 | Rheumatology | News | Article

Gout linked to increased risk for knee replacement

Women with gout are more likely to require total knee replacement for severe knee osteoarthritis than those without gout, study results suggest.

Source:

Osteoarthritis Cartilage 2017; Advance online publication

image credits